Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 1;28(11):2670-2679.
doi: 10.1093/annonc/mdx360.

Long-term toxicity of cisplatin in germ-cell tumor survivors

M Chovanec  1 , M Abu Zaid  2 , N Hanna  2 , N El-Kouri  2 , L H Einhorn  2 , C Albany  3
Affiliations

Long-term toxicity of cisplatin in germ-cell tumor survivors

M Chovanec et al. Ann Oncol. .

Abstract

Context: Testicular germ-cell tumors (GCT) are highly curable. A multidisciplinary approach, including cisplatin-based chemotherapy has resulted in cure in the majority of patients with GCT. Thus, the life expectancy of survivors will extend to many decades post-diagnosis. Late treatment toxicities associated with cisplatin-based chemotherapy may impact their future health.

Objective: To systematically evaluate evidence regarding the long-term toxicity of cisplatin in GCT survivors.

Evidence acquisition: We carried out a critical review of PubMed/Medline in February 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) criteria. Eighty-three publications were selected for inclusion in this analysis.

Evidence synthesis: Included reports evaluated long-term toxicities of cisplatin-based chemotherapy in GCT survivors. Studies reporting neuro- and ototoxicity, secondary malignancies, cardiovascular, renal and pulmonary toxicities, hypogonadism and infertility were found. Seven studies (8%) reported genetic underpinnings of long-term toxicities and 3 (4%) and 14 (19%) studies correlated long-term toxicities with circulating platinum levels and cumulative dose of cisplatin, respectively. Significant risks for long-term toxicities associated with cisplatin and platinum-based regimens were reported. The cumulative dose of cisplatin and circulating platinum were reported as risk factors. Several single-nucleotide polymorphisms identified patients susceptible to cisplatin compared with wild-type individuals.

Conclusions: GCT survivors cured with cisplatin-based chemotherapy are at risk for long-term side-effects. Detection of single-nucleotide polymorphisms could be a valuable tool for predicting long-term toxicities.

Patient summary: Herein, this article summarizes the available evidence of long-term toxicity of cisplatin-based chemotherapy in GCT survivors and provide insights from Indiana University.

Keywords: cisplatin; germ-cell tumor; late toxicity; quality of life; survivor; treatment.

PubMed Disclaimer

References

    1. Hanna N, Einhorn LH.. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol 2014; 32: 3085–3092. - PubMed
    1. Haugnes HS, Bosl GJ, Boer H. et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012; 30: 3752–3763. - PubMed
    1. Travis LB, Beard C, Allan JM. et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010; 102: 1114–1130. - PMC - PubMed
    1. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8: 1777–1781. - PubMed
    1. Fung C, Fossa SD, Williams A, Travis LB.. Long-term morbidity of testicular cancer treatment. Urol Clin North Am 2015; 42: 393–408. - PubMed

Publication types

MeSH terms